10 Einträge von 145 mit factor vitamin
www.cslbehring.ch
Datum der Indexierung 17.02.2023 23:14:18
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring savoir | with scientific | studies notre | that including | disease plus | products research | nous berne | investigator quality | clinical patients | initiated application |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring savoir | with scientific | studies notre | that including | disease plus | products research | nous berne | investigator quality | clinical patients | initiated application |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 04.04.2023 15:01:26
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring notre | with savoir | studies scientific | that including | disease plus | initiated research | investigator berne | application quality | nous patients | products clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring notre | with savoir | studies scientific | that including | disease plus | initiated research | investigator berne | application quality | nous patients | products clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 25.03.2023 20:59:58
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring notre | with savoir | studies scientific | that including | disease plus | initiated research | investigator berne | application quality | nous patients | products clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring notre | with savoir | studies scientific | that including | disease plus | initiated research | investigator berne | application quality | nous patients | products clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung 25.02.2023 08:03:00
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring notre | with savoir | studies scientific | that including | disease plus | initiated research | investigator berne | application quality | nous patients | products clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring notre | with savoir | studies scientific | that including | disease plus | initiated research | investigator berne | application quality | nous patients | products clinical |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036321
www.cslbehring.ch
Datum der Indexierung
erkannte Namen Roger Egger | Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | health quality | investigator more | initiated application |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Roger Egger | Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | health quality | investigator more | initiated application |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 25.03.2023 21:06:02
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring plant | first switzerland | plasma approval | with learn | approved award | patients drug | treatment immunglobulin | production market | factor more | bern company |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring plant | first switzerland | plasma approval | with learn | approved award | patients drug | treatment immunglobulin | production market | factor more | bern company |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 27.03.2023 01:06:24
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 25.02.2023 08:10:17
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring plant | first switzerland | plasma approval | with learn | approved award | patients drug | treatment immunglobulin | production market | factor more | bern company |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring plant | first switzerland | plasma approval | with learn | approved award | patients drug | treatment immunglobulin | production market | factor more | bern company |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
www.cslbehring.ch
Datum der Indexierung 27.02.2023 02:15:14
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
erkannte Namen Grant Provider |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Investigator-Initiated Studies CSL Behring Investigator-Initiated Studies Primary Immunodeficiency (PI) Diseases
Kombination Keywords behring scientific | with including | studies learn | that diseases | disease research | products your | clinical patients | more quality | initiated application | health investigator |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
Factor IX (Recombinant) Albumin Fusion Protein and Antihemophilic Factor (Recombinant) Single Chain, and our plasma products, Human Plasma Derived von Willebrand Factor (HP-vWF/FVIII) concentrate, Fibrinogen, and Prothrombin complex concentrate [huma Vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) Clinical studies and experience with PCCs for urgent reversal prior to emergency surgery or procedures in patients treated with VKAs or DOACs Acquired Bleeding Cli
Text Inhalt Text aus URL
Log Metriken 1036330
www.cslbehring.ch
Datum der Indexierung 17.02.2023 23:16:03
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring plant | first switzerland | plasma approval | with learn | approved award | patients drug | treatment immunglobulin | production market | factor bern | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759
erkannte Namen Ria STAP | Norbert Heimberger |
Subdomain:
extern (outbound) Link/Domain 7 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description CSL Behring – a specialist in biotherapeutics for more than 100 years
Kombination Keywords behring plant | first switzerland | plasma approval | with learn | approved award | patients drug | treatment immunglobulin | production market | factor bern | company more |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
factors in Lengnau. At least 300 new jobs will be created and, over a period of five years, an investment of over 400 million Swiss francs will be made. From 2019, three new recombinant coagulating factors will be produced and marketed around the wor vitamin K antagonists in adults with acute serious bleeding. In December, Kcentra® was also approved for reversing the effects of vitamin K antagonists on patients who require emergency surgery. CSL Behring markets Kcentra® as Ber
Text Inhalt Text aus URL
Log Metriken 32759